Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.60 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955269 | 1.00 | FOLH1 (0.60) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9697060 | 0.96 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL19307785 | 0.96 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL19925534 | 0.96 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL9698236 | 0.96 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL24238520 | 0.96 | FOLH1 (0.64) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL2921260 | 0.91 | FOLH1 (0.59) | FOLH1MMEECE1 | |
| SCHEMBL910423 | 0.91 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL910233 | 0.91 | FOLH1 (0.70) | FOLH1MMEECE1NAALAD2PPARA | |
| SCHEMBL7624700 | 0.91 | FOLH1 (0.59) | FOLH1MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458188-B2 | Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (G) quinazoline trisodium salt | BTG INTERNATIONAL LIMITED (GB) | 2016-10-04 | — | — | US | claimed |
| US-20130345423-A1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | Onyx Pharmaceutical, Inc. (US) | 2013-12-26 | — | — | US | claimed |
| EP-2655398-A2 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | Onyx Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087888-A2 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | ONYX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | claimed |
| US-9458188-B2 | Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (G) quinazoline trisodium salt | BTG INTERNATIONAL LIMITED (GB) | 2016-10-04 | — | — | US | disclosed |
| EP-2655398-B1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | BTG INT LTD (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-20130345423-A1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | Onyx Pharmaceutical, Inc. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2655398-A2 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | Onyx Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087888-A2 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | ONYX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345423-A1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | GLUL, QPCT, GLS | FOLH1 94/4885MME 1290/4885ECE1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.